Join to View Full Profile
1575 Beam AveMaplewood, MN 55109
Phone+1 651-232-7970
Dr. Cheema is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 1999 - 2002
Rush University Medical CenterResidency, Internal Medicine, 1996 - 1999
Government Medical College AmritsarClass of 1995
Certifications & Licensure
WI State Medical License 2003 - 2027
AR State Medical License 1999 - 2026
MN State Medical License 2006 - 2026
FL State Medical License 2022 - 2025
TX State Medical License 2022 - 2025
IL State Medical License 1996 - 1999
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2015-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
Publications & Presentations
PubMed
- 21 citationsSWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Canc...Rachna T Shroff, Gentry King, Sarah Colby, Aaron J Scott, Mitesh J Borad
Journal of Clinical Oncology. 2025-02-10 - 2 citationsCYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108.Vered Stearns, Anne ONeill, Bryan P Schneider, Todd C Skaar, Minetta C Liu
Breast Cancer Research and Treatment. 2025-02-01 - 27 citationsLenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant ErythropoietinAlan F. List, Zhuoxin Sun, Amit Verma, John M. Bennett, Rami S. Komrokji
Journal of Clinical Oncology. 2021-01-13
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:










